atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of...
Pharmaceutical
Immuron Receives FDA Approval for Travelan IND Application
Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate...
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and...
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
OSLO, Norway, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the...
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate...
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
Total considerations of up to USD 83 million with the majority secured for Phase 2 development of the multivalent MVA-BN®...
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
Montrouge, France, December 23, 2022 DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial ...
Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan
Japanese regulatory authority granted marketing authorization to Basilea’s license partner, Asahi Kasei PharmaIntravenous and oral use of Cresemba approved for...
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was...
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complicationNEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE)...
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,...
Update on Proposed Acquisition of Grupo Somar
MIAMI and BARRANQUILLA, Colo., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a...
Galapagos announces changes to Executive Committee
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee...
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics , a clinical-stage drug discovery and development company focusing on novel...